T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...

Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet ...

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as ...

Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response ...

CAR architecture has evolved through four generations. The first relied solely on CD3ζ and lacked potency. Second-generation receptors added either CD28 or 4-1BB costimulation, striking a balance ...

A tumor “don’t‑eat‑me” shield also hides pro‑immune danger signals; new antibodies that unmask this hidden cue could make cancers more vulnerable to immune attack.